Millennium Initiates Phase II Trial ofProstate Cancer Compound

CAMBRIDGE, Mass., SEPTEMBER 11, 2009 – Takeda Pharmaceutical Company Limited (TSE:4502) and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17, 20 lyase[*1] in both the testes and adrenal glands, suppressing the production of androgen.